Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection

International Journal of Experimental Pathology

Volumn 91, Issue 6, 2010, Pages 500-505

  Ibrahem, Salih ^a   Seth, Rashmi ^b   O'Sullivan, Brendan ^c   Fadhil, Wakkas ^a   Taniere, Philippe ^c   Ilyas, Mohammad ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Formalin fixed paraffin embedded; High resolution melting; Mutation detection; PCR; Pyrosequencing

Indexed keywords

DNA;

ALLELE; ARTICLE; CODON; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENETIC PROCEDURES; HIGH RESOLUTION MELTING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTANT; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE B RAF; ONCOGENE K RAS; PRIORITY JOURNAL; PYROSEQUENCING; QUICK MULTIPLEX CONSENSUS POLYMERASE CHAIN REACTION; WILD TYPE;

ALLELES; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; HUMANS; LIMIT OF DETECTION; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 78649516331     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2010.00733.x     Document Type: Article

References (25)

1. Van Den Boom D., Ehrich M. (2007) Discovery and identification of sequence polymorphisms and mutations with MALDI-TOF MS. Methods Mol. Biol. 366, 287-306.
2. Cunningham D., Humblet Y., Siena S. et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345.
3. De Roock W., Piessevaux H., De Schutter J. et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19, 508-515.
4. Di Nicolantonio F., Martini M., Molinari F. et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712.
5. Do H., Krypuy M., Mitchell P.L. et al. (2008) High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8, 142.
6. Dufort S., Richard M.J., De Fraipont F. (2009) Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumour tissues. Anal. Biochem. 391, 166-168.
7. Fadhil W., Ibrahem S., Seth R. et al. (2010) Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue. J. Clin. Pathol. 63, 134-140.
8. Gupta V., Arora R., Ranjan A. et al. (2005) Gel-based nonradioactive single-strand conformational polymorphism and mutation detection: limitations and solutions. Methods Mol. Biol. 291, 247-261.
9. Ilyas M., Straub J., Tomlinson I.P. et al. (1999) Genetic pathways in colorectal and other cancers. Eur. J. Cancer 35, 1986-2002.
10. Janne P.A., Borras A.M., Kuang Y. et al. (2006) A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin. Cancer Res. 12, 751-758.
11. Karapetis C.S., Khambata-Ford S., Jonker D.J. et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765.
12. Koren-Michowitz M., Shimoni A., Vivante A. et al. (2008) A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk. Res. 32, 421-427.
13. Lee J.W., Soung Y.H., Kim S.Y. et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11, 2879-2882.
14. Lievre A., Bachet J.B., Boige V. et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26, 374-379.
15. Loupakis F., Ruzzo A., Cremolini C. et al. (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101, 715-721.
16. Packham D., Ward R.L., Ap Lin V. et al. (2009) Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Diagn. Mol. Pathol. 18, 62-71.
17. Parsons D.W., Wang T.L., Samuels Y. et al. (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436, 792.
18. Peyret N., Seneviratne P.A., Allawi H.T. et al. (1999) Nearest-neighbor thermodynamics and NMR of DNA sequences with internal A.A, C.C, G.G, and T.T mismatches. Biochemistry 38, 3468-3477.
19. Pichler M., Balic M., Stadelmeyer E. et al. (2009) Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J. Mol. Diagn. 11, 140-147.
20. Seth R., Crook S., Ibrahem S. et al. (2009a) Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in colorectal cancer. Gut 58, 1234-1241.
21. Seth R., Keeley J., Abu-Ali G. et al. (2009b) The putative tumour modifier gene ATP5A1 is not mutated in human colorectal cancer cell lines but expression levels correlate with TP53 mutations and chromosomal instability. J. Clin. Pathol. 62, 598-603.
22. Van Cutsem E., Kohne C.H., Hitre E. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417.
23. Weiner L.M., Dhodapkar M.V., Ferrone S. (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373, 1033-1040.
24. Whitehall V., Tran K., Umapathy A. et al. (2009) A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J. Mol. Diagn. 11, 543-552.
25. Wittwer C.T., Reed G.H., Gundry C.N. et al. (2003) High-resolution genotyping by amplicon melting analysis using LCGreen. Clin. Chem. 49, 853-860.